Comparative Pharmacology
Head-to-head clinical analysis: FAMCICLOVIR versus FOSCAVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMCICLOVIR versus FOSCAVIR.
FAMCICLOVIR vs FOSCAVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famciclovir is a prodrug of penciclovir, which inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate, thus inhibiting viral DNA replication. It has activity against herpes simplex virus (HSV-1, HSV-2), varicella-zoster virus (VZV), and Epstein-Barr virus (EBV).
Foscarnet is a pyrophosphate analog that selectively inhibits viral DNA polymerase and reverse transcriptase by binding to the pyrophosphate binding site, preventing the cleavage of pyrophosphate from deoxynucleotide triphosphates, thereby inhibiting viral DNA synthesis. It does not require activation by viral thymidine kinase, making it active against acyclovir-resistant HSV and VZV, and ganciclovir-resistant CMV.
500 mg orally three times daily for 7 days for herpes zoster; 125 mg twice daily for 5 days for recurrent genital herpes; 250 mg three times daily for 7 days for first-episode genital herpes; 500 mg twice daily for 7 days for recurrent herpes labialis.
Induction: 60 mg/kg IV every 8 hours for 2-3 weeks, then maintenance: 90-120 mg/kg IV once daily. Administer as a 2-hour infusion via central line.
None Documented
Clinical Note
moderateFamciclovir + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Famciclovir."
Clinical Note
moderateFamciclovir + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Famciclovir."
Clinical Note
moderateFamciclovir + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Famciclovir."
Clinical Note
moderateFamciclovir + Fluconazole
None Documented
Terminal half-life of penciclovir is 2-3 hours in healthy adults, prolonged to 3-6 hours in hepatic impairment and >20 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life is approximately 3-5 hours in patients with normal renal function; can extend to 48-120 hours in severe renal impairment (CrCl <20 mL/min), requiring dose adjustment and therapeutic drug monitoring.
Renal elimination: ~60% as penciclovir (active metabolite) and <10% as unchanged famciclovir; biliary/fecal: <5%; the remainder is metabolized to inactive compounds.
Primarily renal excretion (>80% as unchanged drug) via glomerular filtration and tubular secretion; minimal biliary/fecal elimination (<5%).
Category A/B
Category C
Antiviral
Antiviral
"The metabolism of Fluconazole can be decreased when combined with Famciclovir."